Latest News

December 10, 2024

Press Release: Autologous stem cell transplants do not improve survival for mantle cell lymphoma patients with undetectable MRD, clinical trial shows

December 4, 2024

Upfront treatment and early intervention to get attention at ASH 2024, including mantle cell lymphoma with the striking results of study EA4151

November 26, 2024

WATCH: David Schiff discusses the striking survival improvement for patients with low-grade brain tumors found in study E3F05

November 26, 2024

The November 2024 News from ECOG-ACRIN blog is now available

November 25, 2024

Press Release: Clinical trial finds that adding the chemotherapy pill temozolomide to radiation therapy improves survival in adult patients with a slow-growing type of brain tumor

November 25, 2024

Press Release: ECOG-ACRIN adds a late-breaking abstract to its ASH 2024 presentation line-up

November 22, 2024

Press Release: ECOG-ACRIN appoints seven researchers to scientific committee leadership positions

October 30, 2024

ECOG-ACRIN and Caris partner to learn more from the TAILORx trial

October 30, 2024

WATCH: Behind the ECOG-ACRIN E1910 trial with lead investigator Dr. Mark Litzow


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
44

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group